ArticleAntiviral research2010
Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models.
Article in Antiviral research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 71 citations in OpenAlex.
- Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome.Signal transduction and targeted therapy · 2021Trial
- Efficacy of favipiravir treatment for patients with severe fever with thrombocytopenia syndrome assessed with a historical control.Antimicrobial agents and chemotherapy · 2025Observational
- Two Human Cases of Fatal Meningoencephalitis Associated with Potosi and Lone Star Virus Infections, United States, 2020-2023.Emerging infectious diseases · 2025Article
- Favipiravir Treatment Prolongs Survival in a Lethal BALB/c Mouse Model of Ebinur Lake Virus Infection.Viruses · 2024Article
- Transfusion-Transmitted Cache Valley Virus Infection in a Kidney Transplant Recipient With Meningoencephalitis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- New Pyrazine Conjugates: Synthesis, Computational Studies, and Antiviral Properties against SARS-CoV-2.ChemMedChem · 2021Article
- Induced intra- and intermolecular template switching as a therapeutic mechanism against RNA viruses.Molecular cell · 2021Article
- Article
- Favipiravir in Therapy of Viral Infections.Journal of clinical medicine · 2021Review
- Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.Pharmacology & therapeutics · 2020Review
- Antivirals in medical biodefense.Virus genes · 2020Review
- New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections.Chemistry, an Asian journal · 2019Review
- Synergistic lethal mutagenesis of hepatitis C virus.Antimicrobial agents and chemotherapy · 2019Article
- Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis.Antimicrobial agents and chemotherapy · 2017Article
- Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.Journal of microbiology (Seoul, Korea) · 2017Review
- Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir.Journal of virology · 2017Article
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2017Review
- Article
- Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.Antimicrobial agents and chemotherapy · 2015Article
- Ebola virus disease in nonendemic countries.Journal of the Formosan Medical Association = Taiwan yi zhi · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Several studies have reported favipiravir (T-705) to be effective in treating a number of viral diseases modeled in rodent systems. Notably, the related pyrazine derivative, T-1106, was found to be more effective than T-705 in treating yellow fever virus infection in hamsters. Based on these findings, we hypothesized that T-1106 may be more effective in treating hepatotropic Punta Toro virus (PTV, Phlebovirus) infection in rodents. In cell culture, the inhibitory concentrations of the compounds against various phleboviruses ranged from 3 to 55microM for T-705 and from 76 to 743microM for T-1106. In PTV-challenged hamsters, a model that generally presents with high liver viral loads, T-1106 was more effective at reducing mortality. However, in mice infected with PTV, a model wherein systemic infection is more prominent, the greater efficacy exhibited by T-1106 in the hamster system was not apparent. In contrast, T-705 was superior in preventing mortality in hamsters challenged with Pichinde virus (PICV, Arenavirus), an infection characterized as diffuse and pantropic. Remarkably, T-1106 has proven more active in vivo than would have been expected from our cell culture results, and our in vivo findings suggest that it is more effective in infections characterized predominantly by high levels of hepatic viral burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.